These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23887618)

  • 21. Clinical and structural remission rates increased annually and radiographic progression was continuously inhibited during a 3-year administration of tocilizumab in patients with rheumatoid arthritis: A multi-center, prospective cohort study by the Michinoku Tocilizumab Study Group.
    Hirabayashi Y; Munakata Y; Miyata M; Urata Y; Saito K; Okuno H; Yoshida M; Kodera T; Watanabe R; Miyamoto S; Ishii T; Nakazawa S; Takemori H; Ando T; Kanno T; Komagamine M; Kato I; Takahashi Y; Komatsuda A; Endo K; Murai C; Takakubo Y; Miura T; Sato Y; Ichikawa K; Konta T; Chiba N; Muryoi T; Kobayashi H; Fujii H; Sekiguchi Y; Hatakeyama A; Ogura K; Sakuraba H; Asano T; Kanazawa H; Suzuki E; Takasaki S; Asakura K; Sugisaki K; Suzuki Y; Takagi M; Nakayama T; Watanabe H; Miura K; Mori Y;
    Mod Rheumatol; 2016 Nov; 26(6):828-835. PubMed ID: 26934116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
    Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
    Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Rheumatoid Arthritis - New Treatment Options].
    Fiehn C
    Dtsch Med Wochenschr; 2017 Dec; 142(24):1844-1848. PubMed ID: 29207429
    [No Abstract]   [Full Text] [Related]  

  • 24. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study.
    Nishimoto N; Amano K; Hirabayashi Y; Horiuchi T; Ishii T; Iwahashi M; Iwamoto M; Kohsaka H; Kondo M; Matsubara T; Mimura T; Miyahara H; Ohta S; Saeki Y; Saito K; Sano H; Takasugi K; Takeuchi T; Tohma S; Tsuru T; Ueki Y; Yamana J; Hashimoto J; Matsutani T; Murakami M; Takagi N
    Mod Rheumatol; 2014 Jan; 24(1):17-25. PubMed ID: 24261754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rheumatoid arthritis: IL-6 inhibition in RA--déjà vu all over again?
    Ruderman EM
    Nat Rev Rheumatol; 2015 Jun; 11(6):321-2. PubMed ID: 25907702
    [No Abstract]   [Full Text] [Related]  

  • 26. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
    Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
    Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab.
    Tanaka Y; Martin Mola E
    Ann Rheum Dis; 2014 Sep; 73(9):1595-7. PubMed ID: 24833786
    [No Abstract]   [Full Text] [Related]  

  • 28. [Pharmacotherapy of rheumatoid arthritis: the 21st century].
    Nasonov EL
    Klin Med (Mosk); 2005; 83(6):8-12. PubMed ID: 16075638
    [No Abstract]   [Full Text] [Related]  

  • 29. Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA.
    Iannone F; Ferraccioli G; Sinigaglia L; Favalli EG; Sarzi-Puttini P; Atzeni F; Gorla R; Bazzani C; Govoni M; Farina I; Gremese E; Carletto A; Giollo A; Galeazzi M; Foti R; Bianchino L; La Grasta L; Lapadula G
    Clin Rheumatol; 2018 Feb; 37(2):315-321. PubMed ID: 28980085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
    Akiyama M; Kaneko Y; Kondo H; Takeuchi T
    Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Rheumatoid arthritis: strategies for biotherapy].
    Nau JY
    Rev Med Suisse; 2012 Oct; 8(358):1988-9. PubMed ID: 23198655
    [No Abstract]   [Full Text] [Related]  

  • 32. Tocilizumab in a patient with newly diagnosed rheumatoid arthritis secondary to checkpoint inhibitor therapy.
    Pirker I; Rubbert-Roth A; von Kempis J; Fehr M; Neumann T
    Clin Exp Rheumatol; 2020; 38(3):573-574. PubMed ID: 31994482
    [No Abstract]   [Full Text] [Related]  

  • 33. Comment on "Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks" by Yokoe et al.
    Nagashima T; Okazaki H; Kamata Y; Minota S
    Mod Rheumatol; 2012 Aug; 22(4):638-9; authoe reply 640-2. PubMed ID: 22669601
    [No Abstract]   [Full Text] [Related]  

  • 34. Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study.
    Sanmarti R; Inciarte-Mundo J; Estrada-Alarcon P; Garcia-Manrique M; Narvaez J; Rodriguez-Moreno J; Gomez-Centeno A; Pascal M; Yagüe J
    Ann Rheum Dis; 2015 Aug; 74(8):e42. PubMed ID: 25805737
    [No Abstract]   [Full Text] [Related]  

  • 35. Toxidermia under treatment with tocilizumab for rheumatoid arthritis.
    Fechtenbaum M; Banse C; Boyard-Lasselin P; Goëb V
    Joint Bone Spine; 2015 Jan; 82(1):69-70. PubMed ID: 25048098
    [No Abstract]   [Full Text] [Related]  

  • 36. Ups and downs in the treatment strategies of rheumatoid arthritis.
    Schipper LG; van Riel PL
    Rheumatology (Oxford); 2011 May; 50(5):818-20. PubMed ID: 20663813
    [No Abstract]   [Full Text] [Related]  

  • 37. Remission in inflammatory arthritis: a new immunological target.
    Saleem B; Walsh CA; Emery P
    Immunotherapy; 2011 Apr; 3(4):459-63. PubMed ID: 21463185
    [No Abstract]   [Full Text] [Related]  

  • 38. Kinase inhibition--a new approach to the treatment of rheumatoid arthritis.
    Fox DA
    N Engl J Med; 2012 Aug; 367(6):565-7. PubMed ID: 22873537
    [No Abstract]   [Full Text] [Related]  

  • 39. Towards an individualised target concentration of adalimumab in rheumatoid arthritis.
    Ducourau E; Ternant D; Lequerré T; Fuzibet P; Le Loët X; Watier H; Goupille P; Paintaud G; Vittecoq O; Mulleman D
    Ann Rheum Dis; 2014 Jul; 73(7):1428-9. PubMed ID: 24550169
    [No Abstract]   [Full Text] [Related]  

  • 40. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
    Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
    PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.